Dr. Clemens Steegborn is a Professor and Chair of Biochemistry at the University of Bayreuth, Germany.

The work in Dr. Steegborn’s lab focuses on the structural, biochemical, and enzymatic characterization of signaling enzymes and their interactions with physiological ligands and drugs, and the structure-assisted development of small molecules for modulating them. His lab has a long and successful record of accomplishment of such studies, mostly on cyclic nucleotide signaling enzymes, in particular soluble adenylyl cyclase, and the NAD+-dependent deacylases of the Sirtuin family. At University of Bayreuth, Dr. Steegborn has served as a Deputy Director of the Institute for Biomacromolecules (BioMac), Speaker of the profile area Molecular Biosciences, and Co-Speaker of the Bayreuth Center for Molecular Biosciences (BZMB). He further served as a Speaker of the Structural Biology group within the German Society for Biochemistry and Molecular Biology (GBM) and as a member of the editorial board of the Impact journal “Aging”. He is a member of the scientific advisory boards of the biomedical startup Ovibio and he actively works with Ovibio on the structure-assisted development of novel therapeutics for aging-related diseases.  

After his diploma in Biochemistry from the University of Bayreuth, Dr. Steegborn performed his PhD research with Nobel Laureate Robert Huber at the Max-Planck-Institute for Biochemistry, focusing on protein crystallographic and enzymatic studies. During his postdoctoral training in biochemistry and structural biology with Hao Wu at Weill Cornell Medical College in New York, NY, he studied nucleotide-regulated signaling proteins and soluble adenylyl cyclase. Dr. Steegborn then started his independent lab as a Junior-Professor in Physiological Chemistry at Ruhr-University Bochum, Germany, in 2005 to study molecular regulation mechanisms in aging and disease, and how to modulate them with drugs. In 2010, he moved to the University of Bayreuth as a Full Professor and Chair in Biochemistry.